CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Bronchiectasis - Management
Basis for recommendation
Mucolytics
- There is insufficient evidence to determine whether mucolytics are of benefit for people with bronchiectasis.
- Experts recommend that these should not be routinely prescribed for the treatment of bronchiectasis [British Thoracic Society, 2010].
Inhaled corticosteroids
- There is insufficient evidence to determine whether inhaled corticosteroids are of benefit for people with bronchiectasis.
- Experts recommend that these should not be routinely prescribed for the treatment of bronchiectasis (unless there is coexistent asthma) [British Thoracic Society, 2010].
Oral corticosteroids
- There is insufficient evidence to determine whether oral corticosteroids are of benefit for people with bronchiectasis.
- Experts recommend that these should not be routinely prescribed for the treatment of bronchiectasis [British Thoracic Society, 2010].
Leukotriene receptor antagonists
- There is insufficient evidence to determine whether leukotriene receptor antagonists are of benefit for people with bronchiectasis.
- Experts recommend that these should not be routinely prescribed for the treatment of bronchiectasis [British Thoracic Society, 2010].
© NHS Institute for Innovation and Improvement